pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$SANASana Biotechnology, Inc.

$SANA2.89000.00%
Seattle, WA, USupdated 3d ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
5
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Preclinical: 1
1Preclinical
Preclinical
SC-451
Type 1 Diabetes (Juvenile Diabetes)

📅 Upcoming

Nov 5, 2026
earnings
$SANA2.89000.00%
in 1mo
Sana Biotechnology, Inc. earnings
Sana Biotechnology, Inc.
→

🕒 Recent(90d)

earnings (1)
Aug 11, 2026
earnings
$SANA2.89000.00%
2mo ago
Sana Biotechnology, Inc. earnings
Sana Biotechnology, Inc.
→
view all catalysts →
🐶 Hiring Signal
next earnings Nov 5, 2026
7 open roles at Sana Biotechnology, Inc. →

Where Sana Biotechnology, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaMetabolic 2
departmentManufacturing / CMC 2R&D / Discovery 2Business Development & Sales 1Finance 1Legal & Compliance 1

News

  • After GLP-1s, biosimilars are the new frontier in direct-to-employer plans
    Fresenius Kabi will sell biosimilars directly to employers. To accomplish that, the drugmaker is working with Eversana-owned Waltz Health, which runs a marketplace that helps employers shop for bet…
    endpoints · 6d ago
  • As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
    As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously…
    fiercebiotech · 20d ago
  • Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
    After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…
    biospace · 2mo ago
  • Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
    An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
    stat · 4mo ago
identifiers
ticker
$SANA
SEC CIK
0001770121
country
US
source
sec_tickers
mentioned in
4news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?